Unlocking the Full Potential of Targeted Glues™ to transform patients’ lives.
Our
Mission
Our mission is to unlock the full potential of Targeted Glues™ to advance a new generation of medicines and make a transformative impact on patients’ lives.
Our Science
Unlike therapies that transiently inhibit a single function of a protein associated with disease onset or progression, targeted protein degradation (TPD) medicines are engineered to destroy and remove pathogenic proteins.
Our novel degraders function as Targeted Glues with class-leading physiochemical properties, enabling us to target a wider tissue and indication scope than traditional approaches.
Antony Mattessich
Chief Executive Officer
Martin Pass PhD
Chief Development Officer
Louise Modis PhD
Chief Scientific Officer
Giles Brown PhD
Senior VP Chemistry
Our People
Our company ethos revolves around a passion for our science and a deep desire to develop the next generation of TPD. We have built a supportive and enabling culture that fosters learning and innovative thinking and encourages all employees to have a voice and be part of the future of TPD as we strive to bring innovative therapies to patients.
Where we are
Amphista is situated on Granta Park, a world-leading science, technology and biopharmaceutical park within the vibrant Cambridge biopharma ecosystem, one of the densest biotech centres globally. Being within the ‘golden triangle’ of London, Oxford and Cambridge offers access to some of the best life sciences talent and expertise globally.